[1]张莉 熊峰.诱导心肌细胞再生研究进展[J].心血管病学进展,2024,(8):727.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.012]
 ZHANG Li,XIONG Feng.Progress of Inducing Cardiomyocyte Regeneration[J].Advances in Cardiovascular Diseases,2024,(8):727.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.012]
点击复制

诱导心肌细胞再生研究进展()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2024年8期
页码:
727
栏目:
综述
出版日期:
2024-08-25

文章信息/Info

Title:
Progress of Inducing Cardiomyocyte Regeneration
作者:
张莉 熊峰
(西南交通大学附属医院 成都市第三人民医院心内科心血管病研究所,四川 成都 610031)
Author(s):
ZHANG LiXIONG Feng
(Department of Cardiology of The Third Peoples Hospital Chengdu,The Affiliated Hospital of Southwest Jiaotong Vniversity,Chengdu 610031,Sichuan,China)
关键词:
心脏再生多能干细胞再生医学重编程
Keywords:
Cardiac regenerationPluripotent stem cellRegenerative medicineReprogramming
DOI:
10.16806/j.cnki.issn.1004-3934.2024.08.012
摘要:
成年哺乳动物心肌细胞在出生后迅速退出细胞周期,当心肌细胞因缺血或其他因素而损伤,残留存活的心肌细胞增殖能力十分有限,取而代之的是不具有收缩能力的纤维组织,从而引发不良心脏重构,最终导致心力衰竭。为了改善心力衰竭患者的预后,开发根本有效的治疗策略至关重要。目前研究已通过多种方法和模型来实现心肌细胞的再生,现综述实现心脏再生方法的研究现状,旨在阐明各种操纵心脏再生和促进心脏损伤后心脏修复的策略,并讨论未来临床应用的前景和挑战。
Abstract:
Adult mammalian cardiomyocytes rapidly withdraw from the cell cycle after birth,When cardiomyocytes are injured by ischemia or other factors,the proliferation ability of surviving cardiomyocytes is very limited,?and they are replaced by fibrous tissue without contractile ability,which causes adverse cardiac remodeling and ultimately leads to heart failure. In order to improve the prognosis of heart failure patients,it is crucial to develop fundamentally effective treatment strategies. At present,many methods and models have been used to realize the regeneration of cardiomyocytes.This review summarizes the research status of the methods of heart regeneration,aims to clarify various strategies for manipulating heart regeneration and promoting heart repair after heart injury,and discusses the prospects and challenges of clinical application in the future

参考文献/References:

[1].Khan A,Gurvitz M. Epidemiology of ACHD:what has changed and what is changing?[J].Prog Cardiovasc Dis,2018,61(3-4):275-281.
[2].Bergmann O,Bhardwaj RD,Bernard S,et al. Evidence for cardiomyocyte renewal in humans[J].?Science,2009,324(5923):98-102.
[3].Wang H,Yang Y,Liu J,et al. Direct cell reprogramming:approaches,mechanisms and progress[J].?Nat Rev Mol Cell Biol, 2021,22(6):410-424.
[4].Qian L,Huang Y,Spencer CI,et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes[J].?Nature,2012,485(7400):593-598.
[5].ayawardena TM,Egemnazarov B,Finch EA,et al. MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes[J].?Circ Res,2012,110(11):1465-1473.
[6].Tani H,Sadahiro T,Yamada Y,et al. Direct reprogramming improves cardiac function and reverses fibrosis in chronic myocardial infarction[J]. Circulation,2023,147(3):223-238.
[7].Lalit PA,Salick MR,Nelson DO,et al. Lineage reprogramming of fibroblasts into proliferative induced cardiac progenitor cells by defined factors[J]. Cell Stem Cell,2016,18(3):354-367.
[8].Muraoka N,Yamakawa H,Miyamoto K,et al. MiR-133 promotes cardiac reprogramming by directly repressing Snai1 and silencing fibroblast signatures[J].?EMBO J,2014,33(14):1565-1581.
[9].Yamakawa H,Ieda M. Cardiac regeneration by direct reprogramming in this decade and beyond[J].?Inflamm Regen,2021,41(1):20.
[10].Li CJ,Madhu V,Balian G,et al. Cross-talk between VEGF and BMP-6 pathways accelerates osteogenic differentiation of human adipose-derived stem cells[J].?J Cell Physiol,2015,230(11):2671-2682.
[11].Smart N,Riley PR. The stem cell movement[J].?Circ Res,2008,102(10):1155-1168.
[12].Bolli R,Chugh AR,D’Amario D,et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO):initial results of a randomised phase 1 trial[J].?Lancet,2011,378(9806):1847-1857.
[13].van Berlo JH,Kanisicak O,Maillet M,et al. c-kit+ cells minimally contribute cardiomyocytes to the heart[J].?Nature,2014,509(7500):337-341.
[14].Kawaguchi S,Soma Y,Nakajima K,et al. Intramyocardial transplantation of human iPS cell-derived cardiac spheroids improves cardiac function in heart failure animals[J]. JACC Basic Transl Sci,2021,6(3):239-254.
[15].Makkar RR,Smith RR,Cheng K,et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS):a prospective,randomised phase 1 trial[J].?Lancet,2012,379(9819):895-904.
[16].Makkar RR,Kereiakes DJ,Aguirre F,et al. Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR):a randomized,placebo-controlled,double-blinded trial[J].?Eur Heart J,2020,41(36):3451-3458.
[17].Vagnozzi RJ,Maillet M,Sargent MA,et al. An acute immune response underlies the benefit of cardiac stem?cell therapy[J].?Nature,2020,577(7790):405-409.
[18].Mummery CL,Zhang J,Ng ES,et al. Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes:a methods overview[J].?Circ Res,2012,111(3):344-358.
[19].Liu YW,Chen B,Yang X,et al. Human embryonic stem cell-derived cardiomyocytes restore function in infarcted hearts of non-human primates[J].?Nat Biotechnol,2018,36(7):597-605.
[20].Romagnuolo R,Masoudpour H,Porta-Sánchez A,et al. Human embryonic stem cell-derived cardiomyocytes regenerate the infarcted pig heart but induce ventricular tachyarrhythmias[J].?Stem Cell Reports,2019,12(5):967-981.
[21].Takahashi K,Tanabe K,Ohnuki M,et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors[J].?Cell,2007,131(5):861-872.
[22].Soma Y,Tani H,Morita-Umei Y,et al. Pluripotent stem cell-based cardiac regenerative therapy for heart failure[J]. J Mol Cell Cardiol,2024,187:90-100.
[23].Romagnuolo R,Masoudpour H,Porta-Sánchez A,et al. Human embryonic stem cell-derived cardiomyocytes regenerate the infarcted pig heart but induce ventricular tachyarrhythmias[J].?Stem Cell Reports,2019,12(5):967-981.
[24].Querdel E,Reinsch M,Castro L,et al. Human Engineered Heart Tissue Patches Remuscularize the Injured Heart in a Dose-Dependent Manner[J]. Circulation,2021,143(20):1991-2006.
[25].Lou X,Tang Y,Ye L,et al. Cardiac muscle patches containing four types of cardiac cells derived from human pluripotent stem cells improve recovery from cardiac injury in mice[J]. Cardiovasc Res,2023,119(4):1062-1076.
[26].Miyagawa S,Kainuma S,Kawamura T,et al.Transplantation of IPSC-derived cardiomyocyte patches for ischemic cardiomyopathy[J]. Front Cardiovasc Med,2022,9:950829.
[27].Mohamed TMA,Ang YS,Radzinsky E,et al. Regulation of cell cycle to stimulate adult cardiomyocyte proliferation and cardiac regeneration[J].?Cell,2018,173(1):104-116.e12.
[28].Abouleisa RRE,Salama ABM,Ou Q,et al. Transient cell cycle induction in cardiomyocytes to treat subacute ischemic heart failure[J].?Circulation,2022,145(17):1339-1355.
[29].van Amerongen MJ,Diehl F,Novoyatleva T,et al. E2F4 is required for cardiomyocyte proliferation[J].?Cardiovasc Res,2010,86(1):92-102.
[30].Mahmoud AI,Kocabas F,Muralidhar SA,et al. Meis1 regulates postnatal cardiomyocyte cell cycle arrest[J].Nature,2013,497(7448):249-253.
[31].Li X,Wu F,Günther S,et al. Inhibition of fatty acid oxidation enables heart regeneration in adult mice[J].?Nature,2023,622(7983):619-626.
[32].Feng J,Li Y,Li Y,et al. Versican promotes cardiomyocyte proliferation and cardiac repair[J]. Circulation,2024,149(13):1004-1015.
[33].Wang YT,Lim Y,McCall MN,et al. Cardioprotection by the mitochondrial unfolded protein response requires ATF5[J].?Am J Physiol Heart Circ Physiol,2019,317(2):H472-H478.
[34].Gao F,Liang T,Lu YW,et al. Reduced mitochondrial protein translation promotes cardiomyocyte proliferation and heart regeneration[J].?Circulation,2023,148(23):1887-1906.

相似文献/References:

[1]章澜 黄从新.心外膜与心脏修复再生[J].心血管病学进展,2021,(4):306.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.005]
 ZHANG Lan,HUANG Congxin.Epicardium in Cardiac Repair Regeneration[J].Advances in Cardiovascular Diseases,2021,(8):306.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.005]
[2]曾庆跃 徐娇 施奕 牟钘雨 李双庆.心脏发育关键转录因子与心肌细胞直接重编程的研究进展[J].心血管病学进展,2023,(10):934.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.016]
 ZENG QingyueXU JiaoSHI YiMOU XingyuLI Shuangqing.Transcription Factors for Cardiac Development and Direct Cardiac Reprogramming[J].Advances in Cardiovascular Diseases,2023,(8):934.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.016]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金(82270486);四川省自然科学基金(24NSFSC0262)
更新日期/Last Update: 2024-09-12